Discussion - How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation.
Topic:
Inflammation and microcirculation
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Novartis and Amgen
Event:
ESC Congress 2016
Congress Presentation
About the speakers
Professor Peter Libby
Brigham and Women's Hospital, Boston (United States of America)
35
presentations
6
followers
Professor John Eric Deanfield
University College London, London (United Kingdom of Great Britain & Northern Ireland)
51
presentations
3
followers
4 more presentations in this session
Introduction - The post ACS patient and residual risk.
Speaker: Professor P. Libby (Boston, US)
Inflammation as potential target for therapy to target residual risk post ACS.
Speaker: Doctor P. Ridker (Boston, US)
Beyond statins: the role of ezetimibe in targeting residual risk.
Speaker: Professor C. Packard (Glasgow, GB)
Novel strategies targeting residual risk: the promise of PCSK9 inhibiting therapies.
Speaker: Professor E. Stroes (Amsterdam, NL)
Access the full session
How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation
Speakers:
Professor P. Libby, Professor J. Deanfield, Professor P. Libby, Doctor P. Ridker, Professor C. Packard...
About the event
ESC 365 is supported by
